TCS Launches Agentic AI Platform to Transform Drug Development
Mumbai, August 17, 2026: Tata Consultancy Services (TCS) has launched TCS ADD™ AgentHub, a role-based, enterprise-ready AI platform designed to help pharmaceutical companies deploy agentic AI across drug development and pharmacovigilance at scale.
The new platform is aimed at addressing the challenges pharmaceutical companies face when adopting AI in highly regulated environments, including governance, auditability, data complexity and regulatory compliance.
TCS ADD™ AgentHub Brings Agentic AI to Pharma R&D
Pharmaceutical companies deal with large volumes of data, fragmented systems and increasingly complex regulatory requirements across clinical development and drug safety.
TCS ADD™ AgentHub provides a structured framework in which AI agents can operate with defined roles, human oversight and built-in auditability.
The platform allows pharmaceutical companies to create customised AI agent hubs and deploy them across clinical and pharmacovigilance workflows. According to TCS, the framework is designed to enable faster AI adoption while maintaining regulatory requirements.
Potential Efficiency and Cost Benefits
TCS said solutions powered by its platform have demonstrated significant operational benefits across drug development and drug safety functions.
According to the company:
- Up to 40% efficiency gains have been demonstrated in clinical data management activities.
- Up to 30% reduction in clinical study build effort has been achieved through metadata-driven automation.
- Up to 30% cost savings have been demonstrated in end-to-end safety case processing.
- AI-powered safety agents can reduce quality-control effort by up to 50%.
These figures are based on solutions powered by the platform and represent the potential operational benefits highlighted by TCS.
Human + AI Operating Model
A key feature of TCS ADD™ AgentHub is its Human + AI Operating Model.
Under this approach, AI agents are embedded into enterprise workflows, while human teams continue to retain responsibility for governance and decision-making.
This model is particularly relevant for pharmaceutical companies, where critical processes must meet strict regulatory, quality and audit requirements.
AI Agents Across Clinical Development and Pharmacovigilance
TCS ADD™ AgentHub supports a range of workflows through specialised AI workers.
These include:
- ICSR intake and data entry
- Coding and review
- Literature analysis
- Clinical study design
- Protocol digitisation
- Clinical data review
- SDTM transformation
- Medical monitoring assistance
- Pharmacovigilance activities
TCS said its catalogue of AI agents will continue to evolve according to specific customer requirements and technology environments.
The agents can be deployed progressively, with the company highlighting rapid implementation and minimal integration effort as key advantages.
TCS Focuses on AI-Led Technology Services
The launch of TCS ADD™ AgentHub is part of TCS’s broader strategy to become an AI-led technology services company.
The company is using its proprietary TCS ADD™ suite to develop secure and predictive digital ecosystems for customers across industries.
For the pharmaceutical sector, the focus is on using agentic AI to automate repetitive processes, improve productivity, and allow scientific teams to concentrate on higher-value activities while maintaining appropriate human oversight.
Management Commentary
Debashis Ghosh, President, Lifesciences and Healthcare, TCS, said that TCS ADD™ AgentHub is designed to help customers accelerate drug development through agentic AI at scale.
He said the platform supports a shift toward more proactive, scalable, and audit-ready operations in an evolving regulatory environment.
The company also sees AI agents working alongside humans as an important part of the future of drug development, to drive innovation while supporting patient safety.
About Tata Consultancy Services
Tata Consultancy Services (TCS) is a global technology services, consulting and business solutions company and part of the Tata Group.
Founded in 1968, TCS serves customers across 56 countries through a global network that includes 194 service delivery centres.
The company reported consolidated revenue of more than US$30 billion for the financial year ended March 31, 2026, according to the press release.
TCS is increasingly focusing on artificial intelligence across its technology services portfolio and has set an aspiration to become the world’s largest AI-led technology services company.
The launch of TCS ADD™ AgentHub strengthens TCS’s positioning in the rapidly developing enterprise AI and agentic AI market.
Its focus on highly regulated industries such as pharmaceuticals could provide opportunities for TCS to expand AI-led services beyond traditional IT outsourcing and consulting.
For investors, the key areas to watch will be the commercial adoption of AgentHub, customer deployments, recurring AI-led revenue opportunities, and the broader impact of AI on TCS’s growth and margins.
Company: Tata Consultancy Services Limited
NSE Symbol: TCS
BSE Scrip Code: 532540
Announcement Date: August 17, 2026
This article is based on the company’s press release dated August 17, 2026 and is intended for informational purposes only. It should not be considered investment advice